Sight Sciences, Inc. (NASDAQ:SGHT – Get Free Report) EVP Manohar K. Raheja bought 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The stock was acquired at an average cost of $2.73 per share, with a total value of $27,300.00. Following the transaction, the executive vice president now owns 145,000 shares of the company’s stock, valued at $395,850. This represents a 7.41 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Sight Sciences Stock Performance
NASDAQ SGHT opened at $2.72 on Friday. Sight Sciences, Inc. has a 52-week low of $2.17 and a 52-week high of $8.45. The company has a 50-day simple moving average of $2.80 and a 200 day simple moving average of $4.25. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18. The company has a market capitalization of $139.63 million, a PE ratio of -2.67 and a beta of 2.52.
Sight Sciences (NASDAQ:SGHT – Get Free Report) last posted its earnings results on Wednesday, March 5th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01). The business had revenue of $19.07 million during the quarter, compared to analysts’ expectations of $18.98 million. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. During the same quarter in the previous year, the business earned ($0.22) EPS. On average, research analysts predict that Sight Sciences, Inc. will post -0.99 EPS for the current year.
Analyst Ratings Changes
Read Our Latest Analysis on Sight Sciences
Institutional Investors Weigh In On Sight Sciences
Several hedge funds have recently bought and sold shares of SGHT. ProShare Advisors LLC bought a new stake in shares of Sight Sciences in the 4th quarter worth approximately $36,000. Dynamic Technology Lab Private Ltd purchased a new position in Sight Sciences during the 4th quarter valued at $40,000. Arkadios Wealth Advisors purchased a new stake in shares of Sight Sciences in the 4th quarter worth about $47,000. WealthTrust Asset Management LLC purchased a new stake in shares of Sight Sciences in the 4th quarter worth about $48,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Sight Sciences in the 4th quarter worth about $50,000. 55.51% of the stock is currently owned by institutional investors.
About Sight Sciences
Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
Featured Stories
- Five stocks we like better than Sight Sciences
- What is a Stock Market Index and How Do You Use Them?
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Investing In Preferred Stock vs. Common Stock
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- How to Most Effectively Use the MarketBeat Earnings Screener
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.